CHINA SXT PHARMACEUTICALS IN (SXTC) Stock Fundamental Analysis

NASDAQ:SXTC • VGG2161P1577

2.375 USD
+0.12 (+5.09%)
At close: Feb 20, 2026
2.22 USD
-0.15 (-6.53%)
Pre-Market: 2/23/2026, 8:03:03 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

SXTC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While SXTC seems to be doing ok healthwise, there are quite some concerns on its profitability. SXTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • SXTC had negative earnings in the past year.
  • In the past year SXTC has reported a negative cash flow from operations.
  • SXTC had negative earnings in each of the past 5 years.
  • SXTC had negative operating cash flow in 4 of the past 5 years.
SXTC Yearly Net Income VS EBIT VS OCF VS FCFSXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -33.66%, SXTC is in line with its industry, outperforming 48.44% of the companies in the same industry.
  • The Return On Equity of SXTC (-43.84%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -33.66%
ROE -43.84%
ROIC N/A
ROA(3y)-16.24%
ROA(5y)-14.76%
ROE(3y)-28%
ROE(5y)-27.24%
ROIC(3y)N/A
ROIC(5y)N/A
SXTC Yearly ROA, ROE, ROICSXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

1.3 Margins

  • The Gross Margin of SXTC (21.74%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of SXTC has declined.
  • SXTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-16.61%
SXTC Yearly Profit, Operating, Gross MarginsSXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • SXTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SXTC has more shares outstanding
  • Compared to 5 years ago, SXTC has more shares outstanding
  • SXTC has a better debt/assets ratio than last year.
SXTC Yearly Shares OutstandingSXTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20K 40K 60K 80K
SXTC Yearly Total Debt VS Total AssetsSXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • SXTC has an Altman-Z score of -1.68. This is a bad value and indicates that SXTC is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -1.68, SXTC perfoms like the industry average, outperforming 46.35% of the companies in the same industry.
  • A Debt/Equity ratio of 0.05 indicates that SXTC is not too dependend on debt financing.
  • SXTC has a Debt to Equity ratio (0.05) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -1.68
ROIC/WACCN/A
WACC6.88%
SXTC Yearly LT Debt VS Equity VS FCFSXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M 15M

2.3 Liquidity

  • A Current Ratio of 4.37 indicates that SXTC has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 4.37, SXTC is doing good in the industry, outperforming 62.50% of the companies in the same industry.
  • A Quick Ratio of 4.24 indicates that SXTC has no problem at all paying its short term obligations.
  • The Quick ratio of SXTC (4.24) is better than 63.02% of its industry peers.
Industry RankSector Rank
Current Ratio 4.37
Quick Ratio 4.24
SXTC Yearly Current Assets VS Current LiabilitesSXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • SXTC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -102.65%.
  • SXTC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.42%.
  • Measured over the past years, SXTC shows a very negative growth in Revenue. The Revenue has been decreasing by -19.53% on average per year.
EPS 1Y (TTM)-102.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.24%
Revenue 1Y (TTM)-15.42%
Revenue growth 3Y-12.51%
Revenue growth 5Y-19.53%
Sales Q2Q%-24.46%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SXTC Yearly Revenue VS EstimatesSXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SXTC. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTC Price Earnings VS Forward Price EarningsSXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTC Per share dataSXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SXTC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CHINA SXT PHARMACEUTICALS IN

NASDAQ:SXTC (2/20/2026, 8:06:33 PM)

Premarket: 2.22 -0.15 (-6.53%)

2.375

+0.12 (+5.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-31
Earnings (Next)N/A
Inst Owners0.27%
Inst Owner Change136.35%
Ins Owners35.32%
Ins Owner ChangeN/A
Market Cap2.28M
Revenue(TTM)1.54M
Net Income(TTM)-8.87M
Analysts0
Price TargetN/A
Short Float %N/A
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.48
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 0.11
EV/EBITDA N/A
EPS(TTM)-161.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.86
FCFYN/A
OCF(TTM)-2.85
OCFYN/A
SpS1.6
BVpS21.08
TBVpS21.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.66%
ROE -43.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.74%
FCFM N/A
ROA(3y)-16.24%
ROA(5y)-14.76%
ROE(3y)-28%
ROE(5y)-27.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-16.61%
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.37
Quick Ratio 4.24
Altman-Z -1.68
F-Score3
WACC6.88%
ROIC/WACCN/A
Cap/Depr(3y)11.31%
Cap/Depr(5y)15.68%
Cap/Sales(3y)1.35%
Cap/Sales(5y)1.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-102.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.24%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.42%
Revenue growth 3Y-12.51%
Revenue growth 5Y-19.53%
Sales Q2Q%-24.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-235.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1614.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2391.55%
OCF growth 3YN/A
OCF growth 5YN/A

CHINA SXT PHARMACEUTICALS IN / SXTC FAQ

What is the ChartMill fundamental rating of CHINA SXT PHARMACEUTICALS IN (SXTC) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SXTC.


What is the valuation status for SXTC stock?

ChartMill assigns a valuation rating of 0 / 10 to CHINA SXT PHARMACEUTICALS IN (SXTC). This can be considered as Overvalued.


What is the profitability of SXTC stock?

CHINA SXT PHARMACEUTICALS IN (SXTC) has a profitability rating of 1 / 10.